Stemedica

STEMEDICA EARNS U.S. PATENT FOR CELLULAR SCAFFOLD ENHANCED BY STEM CELL FACTORS

Stemedica received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent issued in 2012, extends Stemedica’s proprietary technology to therapeutic skin regeneration.

INDONESIA’S BPOM GRANTS IND APPROVAL FOR SCI TO CONDUCT A PHASE II CLINICAL TRIAL USING STEMEDICA’S MESENCHYMAL STEM CELLS TO TREAT ACUTE MYOCARDIAL INFARCTION

Stemedica announces that its research partner The Stem Cell and Cancer Institute (SCI), a subsidiary of PT Kalbe Farma Tbk, Indonesia, received an IND approval in April 2014 from the Badan Pengawas Obat dan Makanan (BPOM, or the Indonesian FDA) for a Phase II study using Stemedica’s mesenchymal stem cells to treat acute myocardial infarction (AMI) in human subjects in Indonesia.

More news >>

Transforming Medicine for the 21st Century

Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.

Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.

Stemdica Overview Video

PRESIDENT OF LEADING SOUTH KOREAN BIOPHARMACEUTICAL COMPANY GREEN CROSS HOLDINGS JOINS STEMEDICA’S BOARD OF DIRECTORS

Stemedica welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors.

Cardio Cell

Applying stem-cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication.

Further information >>